Nanoparticles were created by Liang et al. (2021) to target highly expressed CD44 T24 bladder cancer cells, enabling the usage of hyaluronic acid to be executed when linked with CD44–hyaluronic acid ligands; this nanoparticle system loaded with siRNA and delivered it to cancer sites while also possessing preferential accumulation in vivo for the Bcl-2 oncogene to target bladder cancer [23]. The gene discussed is CD44; the disease is urinary bladder cancer.